Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Phase I Study of LB-100 With Docetaxel in Solid Tumors

This study has been completed.
Information provided by (Responsible Party):
Lixte Biotechnology Holdings, Inc. Identifier:
First received: April 18, 2013
Last updated: September 28, 2016
Last verified: September 2016
No Study Results Posted on for this Study
  Study Status: This study has been completed.
  Study Completion Date: September 2016
  Primary Completion Date: September 2016 (Final data collection date for primary outcome measure)